Business
Harrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020
NASHVILLE, Tenn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13,
About this update from Harrow, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time to discuss the financial results and recent business developments.\n Prior to the open of the market on March 13, 2020, at approximately 8:00 a.m. Eastern Daylight Time / 5:00 a.m. Pacific Daylight Time, Harrow will issue a press release containing a link to its fourth quarter 2019 Letter to Stockholders. The Letter to Stockholders will be archived on the Harrow Investor Relations website in the Archives section, along with the preceding letter, all of which can be found by clicking here. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction and overview of the quarter and outlook for the business. Conference Call Details: U.S. callers: (844) 602-0380International callers: (862) 298-0970Audio-only webcast: please click here Conference Call Replay: A dial in replay of the call will be available until April 13, 2020. The webcast replay will be available until June 13, 2020. U.S. callers: (877) 481-4010, Replay ID: 33135International callers: (919) 882-2331, Replay ID: 33135Webcast: please click here About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here. Forward-Looking Statements This press release contains forward-looking statements within the meanin...